CytomX Therapeutics to Present at Upcoming February Conferences SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be...
CytomX Therapeutics Announces Business Update and Company Milestones for 2026 - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH...
CytomX Therapeutics to Present at Upcoming December Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December. 8th Annual Evercore Healthcare ConferenceDate: Tuesday, December 2, 2025Fireside Chat: 1:45 p.m. ETLocation: Coral Gables, FL Piper Sandler 37th Annual Healthcare ConferenceDate: Thursday, December 4, 2025Fireside Chat: 1:00 p.m. ETLocation: New Y...
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at . In a...
A director at Cytomx Therapeutics Inc sold 101,793 shares at 4.538USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of mask...
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) - SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, tod...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.